Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 857 results for "mylan"

Information Update - Updated consumer information on Mylan Pharmaceuticals nitroglycerin spray recall
Securities Technology Monitor

Health Canada announces Mylan begins voluntary recall of certa...

Health Canada is advising Canadians that Mylan Pharmaceuticals ULC has begun a voluntary recall of certain lots of its Mylan-Nitro Sublingual Spray 0.4 mg Per Metered Dose to the retail level. The recall is a result of the product potentially ... PharmaBiz, 3 days ago
[x]  

Mylan launches generic HIV-1 drug

Mylan Inc., a generic pharmaceutical company, has launched Lamivudine and Zidovudine Tablets USP, 150mg/300mg for the treatment of HIV-1 infection. Lamivudine and Zidovudine Tablets USP, 150mg/300mg are the generic version of Viiv's Combivir. ...
 Individual.com1 week ago Mylan unveils generic Combivir in the US, strengthening its growing antiretroviral franchise in the nation  Individual.com1 week ago Mylan debuts generic of ViiV's Combivir in USA  Pharma Letter1 week ago Mylan Inc. Launches Generic Combivir??  BioSpace1 week ago
[x]  
Business Standard

Venus Remedies surges 18% in three days on marketing tie-up with Mylan

The company has entered into a distribution-cum-outlicensing agreement with Mylan for marketing its generic broad-spectrum antibiotic 'Meropenem' in three European countries. SI Reporter | Mumbai September 10, 2014 Last Updated at 09:42 IST Venus Remedies has ...
 Business Standard1 month ago Venus Pharma inks pact with Mylan for marketing meropenem in 3 European countries  Business Standard1 month ago Venus arm in marketing tie-up with Mylan  Business Standard1 month ago Venus eyes USD 15 mn from meropenem; ties up with Mylan  Business Standard1 month ago
[x]  
Business Standard

Strides fails to get $250 mn of $1.7-bn transaction with Mylan

ides Arcolab, the Bangalore-based publicly held pharmaceutical company, said that it will be getting only $150 million of the $250 million which was supposed to flow into the company as part of an transaction with US-based generics major Mylan. Strides ...
 Business Standard3 weeks ago Strides Arcolab slumps after final settlement with Mylan  Business Standard3 weeks ago Strides to receive USD 150 mn for final settlement from Mylan  Myiris3 weeks ago Strides Arcolab: Updates on Agila transaction  Money Control3 weeks ago
[x]  
Business Standard

Natco Pharma gains 5%; hits 52-week high

company announced that its marketing partner in the USA, Mylan Inc has filed ANDA and has been accepted by USFDA SI Reporter | Mumbai September 1, 2014 Last Updated at 13:25 IST Natco Pharma has gained 5% to Rs 1267 also its 52-week high on the BSE after the ...
 Business Standard1 month ago Natco Pharma hits record high  Business Standard1 month ago Natco Pharma at record high; partner Mylan files ANDA  Money Control1 month ago Natco's partner Mylan Inc files ANDA for generic Copaxone  Business Standard1 month ago

Venus Remedies up on pact with Mylan

In terms of volume, 3.14 lakh shares of the company changed hands at the BSE, while over 11 lakh shares were traded at the NSE during the day. MUMBAI: Shares of Venus Remedies surged over 8 per cent as Venus Pharma GmbH, a subsidiary of the pharma major ...
 Economic Times1 month ago Venus Remedies shares up as unit enters into pact with Mylan  Business Standard1 month ago Venus Remedies surges as unit enters into pact with Mylan  Business Standard1 month ago Venus Remedies extends recent steep rally  Business Standard1 month ago

Biocon up 3% post Mylan's phase-3 trials for Glargine

Kiran Mazumdar Shaw, CMD of the company sees it to be a huge opportunity in the diabetic market and expects the insulin analogue market to grow in double-digits.
 Money Control1 month ago
Business Standard

Gilead inks licensing pacts for Hep C drug with Ranbaxy, Cipla, Mylan, four Indian firms

Seven India-based firms - Ranbaxy, Cipla, Mylan, Cadila, Hetero, Sequent and Strides Arcolab - will produce hepatitis C medicines for distribution in 91 developing countries BS B2B Bureau | New Delhi September 17, 2014 Last Updated at 13:18 IST In what could ...
 Business Standard1 month ago Gilead Sciences picks India to lower drug cost  Asian Age1 month ago Gilead licenses hepatitis C drugs to 7 India-based pharma cos  Business Standard1 month ago

Biocon-Mylan start global phase-3 trials for drug Glargine

The biosimilar insulin drug Glargine targets market of USD 8 billion globally and has been approved in 10 countries already.
 Money Control1 month ago

Natco Pharma`s partner Mylan files ANDA for Copaxone

Natco Pharma , one of the few Indian companies to venture into new drug discovery research, announced that its marketing partner in the USA, Mylan has filed an Abbreviated New Drug Application (ANDA) for a three times a week generic Copaxone (glatiramer ...
 Myiris1 month ago Natco jumps after Mylan files ANDA for Copaxone  Myiris1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - mylan
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less